AILatest
Insilico Medicine and Lilly sign $2.75 billion deal
Insilico Medicine and Eli Lilly have entered a commercialization agreement potentially worth up to $2.75 billion. This partnership aims to advance AI-driven drug development and bring innovative therapies to market.
0 upvotes
What happened
Insilico Medicine and Eli Lilly have entered a commercialization agreement potentially worth up to $2.75 billion.
Why it matters
This partnership aims to advance AI-driven drug development and bring innovative therapies to market.